Ensuring Access to Injectable Generic Drugs - The Case of Intravesical BCG for Bladder Cancer

N Engl J Med. 2017 Apr 13;376(15):1401-1403. doi: 10.1056/NEJMp1615697.

Authors

Benjamin J Davies¹, Thomas J Hwang¹, Aaron S Kesselheim¹

Affiliation

¹ From the Department of Urology, University of Pittsburgh and Hillman Cancer Center, Pittsburgh (B.J.D.); and the Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston (T.J.H., A.S.K.).

PMID: 28402764
DOI: 10.1056/NEJMp1615697

No abstract available

MeSH terms

Administration, Intravesical
Antineoplastic Agents / economics*
Antineoplastic Agents / supply & distribution
Antineoplastic Agents / therapeutic use
BCG Vaccine / supply & distribution*
BCG Vaccine / therapeutic use
Drug Approval
Drug Costs / trends*
Drugs, Generic / supply & distribution*
Drugs, Generic / therapeutic use
Health Care Costs
Health Services Accessibility
Humans
United States
United States Food and Drug Administration
Urinary Bladder Neoplasms / drug therapy*

Substances

Antineoplastic Agents
BCG Vaccine
Drugs, Generic